Raymond James & Associates Genmab A/S Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Genmab A/S stock. As of the latest transaction made, Raymond James & Associates holds 166,149 shares of GMAB stock, worth $4.47 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
166,149
Previous 166,365
0.13%
Holding current value
$4.47 Million
Previous $4.98 Million
16.08%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding GMAB
# of Institutions
232Shares Held
48.5MCall Options Held
6.8KPut Options Held
27.6K-
Alliancebernstein L.P. New York, NY15.2MShares$410 Million0.14% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$137 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA4.23MShares$114 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.77MShares$74.5 Million0.4% of portfolio
-
Wellington Management Group LLP Boston, MA2.31MShares$62.1 Million0.01% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $17.7B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...